As of 2025-12-28, the EV/EBITDA ratio of Summit Therapeutics Inc (SMMT) is -23.07. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. SMMT's latest enterprise value is 13,265.59 mil USD. SMMT's TTM EBITDA according to its financial statements is -575.12 mil USD. Dividing these 2 quantities gives us the above SMMT EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | - | - |
| Forward P/E multiples | - | - |
| Fair Price | - | - |
| Upside | - | - |
| Date | EV/EBITDA |
| 2025-12-23 | -23.04 |
| 2025-12-22 | -23.08 |
| 2025-12-19 | -22.65 |
| 2025-12-18 | -21.64 |
| 2025-12-17 | -21.60 |
| 2025-12-16 | -21.89 |
| 2025-12-15 | -22.08 |
| 2025-12-12 | -22.33 |
| 2025-12-11 | -22.87 |
| 2025-12-10 | -22.81 |
| 2025-12-09 | -21.62 |
| 2025-12-08 | -23.69 |
| 2025-12-05 | -23.29 |
| 2025-12-04 | -23.93 |
| 2025-12-03 | -23.36 |
| 2025-12-02 | -21.91 |
| 2025-12-01 | -21.93 |
| 2025-11-28 | -22.74 |
| 2025-11-26 | -22.65 |
| 2025-11-25 | -22.42 |
| 2025-11-24 | -22.68 |
| 2025-11-21 | -20.54 |
| 2025-11-20 | -20.88 |
| 2025-11-19 | -21.02 |
| 2025-11-18 | -21.34 |
| 2025-11-17 | -21.53 |
| 2025-11-14 | -22.92 |
| 2025-11-13 | -23.22 |
| 2025-11-12 | -23.96 |
| 2025-11-11 | -24.39 |
| 2025-11-10 | -23.27 |
| 2025-11-07 | -23.12 |
| 2025-11-06 | -23.47 |
| 2025-11-05 | -22.98 |
| 2025-11-04 | -22.22 |
| 2025-11-03 | -23.17 |
| 2025-10-31 | -24.06 |
| 2025-10-30 | -23.71 |
| 2025-10-29 | -23.74 |
| 2025-10-28 | -24.48 |
| 2025-10-27 | -24.77 |
| 2025-10-24 | -24.54 |
| 2025-10-23 | -23.86 |
| 2025-10-22 | -24.39 |
| 2025-10-21 | -23.84 |
| 2025-10-20 | -25.52 |
| 2025-10-17 | -26.75 |
| 2025-10-16 | -28.02 |
| 2025-10-15 | -28.89 |
| 2025-10-14 | -27.74 |